Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $0.03.

  • Protalix BioTherapeutics' EPS (Basic) fell 2500.0% to $0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.07, marking a year-over-year increase of 14666.67%. This contributed to the annual value of $0.04 for FY2024, which is 6666.67% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' EPS (Basic) is $0.03, which was down 2500.0% from -$0.05 recorded in Q1 2025.
  • Protalix BioTherapeutics' 5-year EPS (Basic) high stood at $0.29 for Q2 2023, and its period low was -$0.25 during Q2 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.06 (2022), whereas its average is -$0.04.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 56666.67% in 2021, then surged by 36363.64% in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' EPS (Basic) (Quarter) stood at -$0.14 in 2021, then skyrocketed by 50.0% to -$0.07 in 2022, then tumbled by 42.86% to -$0.1 in 2023, then soared by 190.0% to $0.09 in 2024, then plummeted by 66.67% to $0.03 in 2025.
  • Its last three reported values are $0.03 in Q3 2025, -$0.05 for Q1 2025, and $0.09 during Q4 2024.